We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 01, 2019

Rivaroxaban After TAVR

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
A Controlled Trial of Rivaroxaban After Transcatheter Aortic-Valve Replacement
N. Engl. J. Med 2019 Nov 16;[EPub Ahead of Print], GD Dangas, JGP Tijssen, J Wöhrle, L Søndergaard, M Gilard, H Möllmann, RR Makkar, HC Herrmann, G Giustino, S Baldus, O De Backer, AHC Guimarães, L Gullestad, A Kini, D von Lewinski, M Mack, R Moreno, U Schäfer, J Seeger, D Tchétché, K Thomitzek, M Valgimigli, P Vranckx, RC Welsh, P Wildgoose, AA Volkl, A Zazula, RGM van Amsterdam, R Mehran, S Windecker

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading